Thus, we explored the correlation between HER2 amplification and characteristics of immunogenicity and TIME in LUAD contrast to gastric cancer that benefited from immunotherapy (15), and breast cancer that did not (17), to establish a theoretical feasibility of ICIs for HER2-amplified LUAD. The gene discussed is ERBB2; the disease is gastric cancer.